Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia

  • S. Amadori
  • A. M. Testi
  • M. Vignetti
  • A. Spadea
  • P. Fazi
  • A. P. Iori
  • G. Isacchi
  • F. Mandelli
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Treatment of acute myeloid leukemia (AML) frequently induces complete remission (CR) with initial induction chemotherapy. However, long-term disease-free survival is achieved in only a minority of patients, since the majority ultimately relapse [1]. The prognosis of patients who fail to achieve an initial CR or who experience recurrence of their leukemia remains dismal. Results of salvage therapy have been generally disappointing with low response rates and occasional long-term survivors in most studies [2]. Recently, we reported that a combination of intermediate-dose cytosine arabinoside (Ara-C) and mitoxantrone could induce CR in 24/36 (67%) patients with advanced AML, without undue toxicity [3]. Responses were observed in 85% of patients whose initial remission lasted for more than 6 months, but in only 28% and 33% of those with primary refractory disease and shorter remission duration, respectively.

Keywords

Toxicity Leukemia Oncol Resi Etoposide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin RE, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562PubMedGoogle Scholar
  2. 2.
    Hiddemann W, Büchner T (1990) Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment. Blut 60: 163–171PubMedCrossRefGoogle Scholar
  3. 3.
    Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F (1989) Phase II trial of intermediate dose Ara-C (IDAC) with sequential Mitoxantrone ( MITOX) in acute myelogenous leukemia. Leukemia 3: 112–114PubMedGoogle Scholar
  4. 4.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, DonhuijsenAnt R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749PubMedGoogle Scholar
  5. 5.
    Ho AD, Lipp T, Ehninger G, Illiger H-J, Meyer P, Freund M, Hunstein W (1988) Combination of Mitoxantrone and Etoposide in refractory acute myelogenous leukemia. An active and well-tolerated regimen. J Clin Oncol 6: 213–217PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • S. Amadori
    • 1
  • A. M. Testi
    • 1
  • M. Vignetti
    • 1
  • A. Spadea
    • 1
  • P. Fazi
    • 1
  • A. P. Iori
    • 1
  • G. Isacchi
    • 1
  • F. Mandelli
    • 1
  1. 1.Section of Hematology, Department of Human BiopathologyUniversity La SapienzaRomeItaly

Personalised recommendations